Capricor Therapeutics said the FDA asked for more data supporting the efficacy of Deramiocel, the biotech’s off-the-shelf cell therapy for treating the heart complications of Duchenne muscular dystrophy. Those data could come from an ongoing Phase 3 study expected to yield preliminary data soon.
The post FDA Turns Down Capricor Cell Therapy for Cardio Complications of Rare Muscle Disease appeared first on MedCity News.
